Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zibotentan and dapagliflozin study in adults with hypertension
ISRCTN10215858Phase 2Active, not recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of zibotentan and dapagliflozin in essential hypertension (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Unattended seated automated office systolic blood pressure. Started Oct 2025; status: active, not recruiting.
02
Drugs
zibotentandapagliflozin
03
Conditions
essential hypertension
Beyond the preview
Go deeper on ISRCTN10215858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10215858.